Agriculture & Natural Solutions Acquisition Corp Ordinary Shares - Class A ANSC 深 滬
等待開盤 09-27 09:30:00 美东时间
10.96
0.000
0.00%
華盛通- 最 高10.96
- 今 開10.96
- 成交量 557股
- 最 低 10.96
- 昨 收 10.96
- 總市值 4.73亿
- 52周最高 10.98
- 市盈率 靜 361.72
- 換手率 0.00%
- 52周最低 10.35
- 委 比 -72.41%
- 總股本 4312.50万
- 歷史最高 10.98
- 量 比 0.12
- 振 幅 0.00%
- 歷史最低 10.05
- 每 手 1
- 風險率 0.19%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多KBR, Inc. (KBR) Faces Securities Class Action Amid TRANSCOM Contract Termination-Hagens Berman
SAN FRANCISCO, Sept. 22, 2025 /PRNewswire/ -- A new class-action lawsuit is targeting KBR, Inc. (NYSE: KBR), alleging the company made misleading statements to investors in the weeks leading...
09-23 00:45
CERo Therapeutics Secures U.S. And Japanese Patents For CER-1236
Additional patent granted from the Japanese patent office now results in 20 granted patents and allowed applications covering the compound and its underlying technologySOUTH SAN FRANSCISCO, Calif., Sept. 09, 2025 (GLOBE
09-09 20:18
【太平洋医药】医药生物行业周报：资金现跷跷板效应，持续关注创新药催化（附PD-(L)1/VEGF专题研究）
（来源：市场投研资讯） 摘要 本周观点 本周，我们梳理了PD-(L)1/VEGF作用机制、在研产品以及催化剂。 关注PD-(L)1/VEGF赛道，202...
09-01 14:59
Rhythm Pharmaceuticals Announces The FDA Has Accepted Its Supplemental New Drug Application For Setmelanotide To Treat Acquired Hypothalamic Obesity
U.S. Food and Drug Administration accepts sNDA for filing with priority review; sets PDUFA goal date of December 20, 2025 --– European Medicines Agency accepts and validates submission for Type II variation MAA for
08-21 04:03
Surmodics Raises FY2025 Adj EPS Guidance from $(0.62)-$(0.42) to $(0.35)-$(0.20) vs $(0.55) Est; Raises FY2025 Sales Guidance from $114.000M-$117.000M to $116.500M-$118.500M vs $115.686M Est
Fiscal Year 2025 Financial GuidanceSurmodics is increasing its fiscal 2025 total revenue to a range of $116.5 million to $118.5 million, representing a decrease of 8% to 6% compared to fiscal 2024. Excluding SurVeil DCB
08-08 19:05
CERo Therapeutics Doses Second Patient In Phase 1 AML Trial; Reports Early Pharmacokinetic Data With More Than Seven Days Passed Following The Second Patient's Infusion, Monitoring Continues For Key Safety, Tolerability, And Efficacy Endpoints
Second patient in the first cohort is now advancing through protocol-defined evaluations as Company provides promising update on first patient pharmacokinetic resultsSOUTH SAN FRANSCISCO, Calif., July 31, 2025 (GLOBE
07-31 20:11
Reported Saturday, Rhythm Pharmaceuticals Reports Statistically Significant BMI Reductions In Children And Adults Across Multiple Doses And Subgroups In TRANSCEND And SIGNAL Trials
Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity –- Full data from Phase 3 TRANSCEND study underscore potential efficacy of setmelanotide, including with
07-14 14:51
KBR announces resignation of COO Byron Bright
KBR (NYSE:KBR) announced on Wednesday that Byron Bright has resigned from his position as chief operating officer (COO) and will leave the company on July 11, 2025. In January 2025, KBR announced a re...
07-10 04:22
KBR’s Role in TRANSCOM Contract Terminated
KBR ( ($KBR) ) has shared an update. On June 18, 2025, HomeSafe Alliance, a joi...
06-20 20:57
Bristol Myers Squibb Announces First Disclosure Of Primary Analysis Results Of MZL Cohort Of TRANSCEND FL, Phase 2, Single-Arm Study Evaluating Breyanzi In Patients With Relapsed Or Refractory Disease
95.5% of patients with relapsed or refractory marginal zone lymphoma (MZL) treated with lisocabtagene maraleucel (liso-cel) achieved a response, with 62.1% achieving complete response and 88.6% maintaining a response at
06-16 19:00
